(Q30317955)

17 June 2017

title

Respiratory function in late-onset Pompe disease patients receiving long-term enzyme replacement therapy for more than 48 months (English)

1 reference

enzyme replacement therapy

17 June 2017

main subject

0 references

author name string

Ilka Schneider

1

1 reference

17 June 2017

Frank Hanisch

2

1 reference

17 June 2017

Tobias Müller

3

1 reference

17 June 2017

Bernd Schmidt

4

1 reference

17 June 2017

Stephan Zierz

5

1 reference

17 June 2017

publication date

19 November 2012

1 reference

Wiener Medizinische Wochenschrift

17 June 2017

published in

1 reference

17 June 2017

volume

163

1 reference

17 June 2017

issue

1-2

1 reference

17 June 2017

page(s)

40-44

1 reference

https://scigraph.springernature.com/pub.10.1007/s10354-012-0153-5

17 June 2017

exact match

0 references

cites work

The spectrum and diagnosis of acid maltase deficiency.

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0153-5

A randomized study of alglucosidase alfa in late-onset Pompe's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0153-5

Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0153-5

Respiratory insufficiency and limb muscle weakness in adults with Pompe's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0153-5

Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0153-5

Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0153-5

Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0153-5

36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0153-5

Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0153-5

The value of multiple tests of respiratory muscle strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0153-5

Cough peak flows: standard values for children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0153-5

Late onset Pompe disease: Clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0153-5

Effects of enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II: a 2-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-012-0153-5

Supine volume drop and diaphragmatic function in adults with Pompe disease

21 January 2018

1 reference

12 December 2020

Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease

1 reference

12 December 2020

Clinical features of late-onset Pompe disease: a prospective cohort study

1 reference

12 December 2020

Nasal inspiratory pressure: an alternative for the assessment of inspiratory muscle strength?

1 reference

12 December 2020

[A retrospective study of six patients with late-onset Pompe disease]

1 reference

12 December 2020

Molecular diagnosis of German patients with late-onset glycogen storage disease type II

1 reference

12 December 2020

[Glycogenesis Type II (M. Pompe). Selective failure of the respiratory musculature--a rare first symptom]

1 reference

12 December 2020

10.1007/S10354-012-0153-5

Identifiers

DOI

1 reference

Dimensions Publication ID

17 June 2017

1033792321

0 references

1 reference